1-866-598-7166

First-in-Human Study of BMS-986506 in People with Advanced Clear Cell Renal Cell Carcinoma

Trial ID: NCT07195682
Kidney Cancer Type: Clear Cell only


Background:

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. When the cancer has spread or returned after earlier treatments, options can become limited, and new therapies are needed.

This study is testing a new experimental drug called BMS-986506. This is the first time it is being given to people (a “first-in-human” study). Researchers want to learn how safe it is, how well patients tolerate it, and how the body processes the drug.

The hope is that BMS-986506 may offer a new way to slow down or control kidney cancer in the future, especially for people whose disease no longer responds to standard treatments.


The Trial:

The goal of this study is to learn whether the new drug BMS-986506 is safe and well tolerated in people with advanced clear cell renal cell carcinoma (ccRCC). Researchers also want to understand how the body processes the drug and whether it shows any early signs of activity against cancer.

All participants in this study will receive BMS-986506.

This trial is not “blinded”, which means both you and your doctor will know which treatment you are receiving.

 

Basic Eligibility:

  • Confirmed locally advanced or metastatic clear cell renal cell carcinoma

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreTom Baker Cancer Centre Principal InvestigatorNot Given LocationCalgary, AB Trial StatusNot yet recruiting
Kidney Cancer Canada